James Anderson

Dr. Anderson is a diabetologist and endocrinologist who has been in military medicine and the pharmaceutical industry for more than 40 years. A graduate of Centenary College of Louisiana, he earned his M.D. degree from LSU School of Medicine in New Orleans, followed by Internship and Internal Medicine Residency at Charity Hospital in New Orleans. Dr. Anderson began his Fellowship in Endocrinology and Metabolism at LSU and completed it at the Medical College of Virginia in Richmond.

Following his training, he served as Chief of Medicine at the US Army Medical Research Institute for Infectious Diseases, Ft. Detrick, Maryland where he continued his studies of the effect of infection on diabetes as well as worked on biological warfare defense, vaccines, and safe care of patients with high hazard infectious diseases. He also served as the safety physician for the very first Level 3 recombinant DNA experiments performed by the US NIH. Lt. Col. Anderson then moved to Brooke Army Medical Center at Ft Sam Houston, San Antonio, Texas where he served as Chairman of the Department of Clinical Investigation and Consultant to the Surgeon General of the Army for Clinical Investigation. During that time he acquired the Army’s first artificial pancreas to aid in the investigation of immune factors in the etiology of diabetes. While in San Antonio, he also was an independent investigator for Lilly’s development of rDNA human insulin for therapeutic use.

Dr. Anderson then joined Eli Lilly and Company where he was responsible for Lilly’s global clinical diabetes/endocrine development program. He managed diabetes and cardiometabolic drug development, and drove the clinical development, registration and launch of two families of billion dollar diabetes care products, Humulin® (human insulin of rDNA origin) and Humalog®, the first rapid-acting analog of human insulin for which he is one of the inventors. He led the clinical development and was responsible for 6 US NDAs, and had clinical responsibility for all insulin products worldwide. He also evaluated and conducted the initial clinical development of human insulin and insulin analog pre-mixtures, basal insulin analogs, pulmonary and oral insulin as well as a small molecule, oral drugs for type 2 diabetes. Dr. Anderson re-focused the strategic clinical direction for marketed products and investigational drugs, the conduct of global clinical trials and the clinical development of numerous compounds in Phase I- Phase IV. He held pivotal roles directing Lilly’s endocrine products in Japan, global medical-marketing, internal discovery, and in-licensing opportunities. He was the first in the industry to envision and accomplish a strategic concurrent global clinical development and registration program, which secured a first to market position for Lilly’s Humalog. Prior to retiring from Lilly, Dr. Anderson led the initial development of Lilly’s newest drug for diabetes – dulaglutide [Trulicity™] (which is Lilly’s third billion-dollar diabetes drug).

A strong believer in education, Dr. Anderson has served on the medical faculties of LSU School of Medicine, Medical College of Virginia, Uniformed Services University of the Health Sciences, the University of Texas Health Science Center San Antonio, and Indiana University School of Medicine where he is currently a Clinical Associate Professor of Medicine for the Division of Endocrinology and Metabolism.

Internationally recognized, Dr. Anderson is an elected Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK and was a founding board member of the American Association of Pharmaceutical Physicians. He is also a Fellow of the American College of Endocrinology. He is a founding editorial board member of two journals for diabetes, and serves on the editorial boards or is a reviewer for 5 other diabetes/endocrine journals. He has also served in local, regional and national positions with the American Diabetes Association.

In addition to serving as Medical Director for PTS Diagnostics in Indianapolis, he currently holds positions as President and CEO of MitoZyme Inc (Carmel, IN and Boston), CEO of Diabetes and CardioMetabolic Disease Solutions Group (Carmel) and Medical Director of Know Labs (Seattle). Dr. Anderson has served as Senior Scientific Advisor and is currently a member of the Board of Directors for Generex Biotechnology Corporation (Miramar, Florida and Burlington, Ontario).